{"id":"W4281953617","doi":"10.1200/jco.2022.40.16_suppl.7538","title":"Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Tolerability; Gastroenterology; Rituximab; Refractory (planetary science); Toxicity; Progression-free survival; Oncology; Ibrutinib; Leukemia; Overall survival; Adverse effect; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003643168,0.001447574,0.002115598,0.000698724,0.0004694428,0.001212936,0.001213145,0.001450892,0.002943101],"category_scores_gemma":[0.001919552,0.0003670998,0.002730418,0.0005327777,0.0007508994,0.001635375,0.0006733259,0.002936616,0.0007738441],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001435229,"about_ca_system_score_gemma":0.0009107066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00161464,"about_ca_topic_score_gemma":0.002789678,"domain_scores_codex":[0.999067,0.0004178023,0.00005421326,0.000135569,0.0001011995,0.0002242789],"domain_scores_gemma":[0.9981207,0.000415376,0.000523455,0.0001558118,0.0001007177,0.0006839493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9203661,0.0141384,0.01481879,0.0002602872,0.00238378,0.0001521385,0.0001041678,0.001642182,0.002801366,0.00009302705,0.003390689,0.03984901],"study_design_scores_gemma":[0.2949652,0.5671849,0.118816,0.0001340772,0.004811036,0.0005094922,0.0001716974,0.005048013,0.002479328,0.0005375785,0.005258563,0.00008418997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904193,0.004447643,0.0001981459,0.0003478733,0.0001474121,0.0004533647,0.00207701,0.00007193773,0.001837201],"genre_scores_gemma":[0.9909868,0.001213769,0.0004309817,0.0007517708,0.000299294,0.0004796218,0.00424853,0.00001627599,0.001572944],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003643168,"threshold_uncertainty_score":0.01926714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1575472935405038,"score_gpt":0.4610444198356924,"score_spread":0.3034971262951887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}